title: Plasmin substrate binding site cooperativity guides the design of potent peptide aldehyde inhibitors.
abstract: Perioperative bleeding is a cause of major blood loss and is associated with increased rates of postoperative morbidity and mortality. To combat this, antifibrinolytic inhibitors of the serine protease plasmin are commonly used to reduce bleeding during surgery. The most effective and previously widely used of these is the broad range serine protease inhibitor aprotinin. However, adverse clinical outcomes have led to use of alternative serine lysine analogues to inhibit plasmin. These compounds suffer from low selectivity and binding affinity. Consequently, a concerted effort to discover potent and selective plasmin inhibitors has developed. This study used a noncombinatorial peptide library to define plasmin's extended substrate specificity and guide the design of potent transition state analogue inhibitors. The various substrate binding sites of plasmin were found to exhibit a higher degree of cooperativity than had previously been appreciated. Peptide sequences capitalizing on these features produced high-affinity inhibitors of plasmin. The most potent of these, Lys-Met(sulfone)-Tyr-Arg-H [KM(O(2))YR-H], inhibited plasmin with a K(i) of 3.1 nM while maintaining 25-fold selectivity over plasma kallikrein. Furthermore, 125 nM (0.16 μg/mL) KM(O(2))YR-H attenuated fibrinolysis in vitro with an efficacy similar to that of 15 nM (0.20 μg/mL) aprotinin. To date, this is the most potent peptide inhibitor of plasmin that exhibits selectivity against plasma kallikrein, making this compound an attractive candidate for further therapeutic development.
authors.affiliation: Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Queensland 4059, Australia.
authors.forename: Joakim E
authors.initials: JE
authors.lastname: Swedberg
authors.forename: Jonathan M
authors.initials: JM
authors.lastname: Harris
mesh_terms: D000933:Antifibrinolytic Agents / Q000138:chemical synthesis* / Q000494:pharmacology; D007611:Aprotinin / Q000494:pharmacology; D001665:Binding Sites; D015195:Drug Design; D005341:Fibrinolysin / Q000737:chemistry*; D006801:Humans; D007700:Kinetics; D009842:Oligopeptides / Q000138:chemical synthesis* / Q000494:pharmacology
chemical_list: D000933:Antifibrinolytic Agents; D009842:Oligopeptides; C568364:lysyl-methionyl(sulfone)-tyrosyl-arginine; D007611:Aprotinin; D005341:Fibrinolysin